Abstract 498P
Background
In Taiwan, gefitinib, erlotinib, and afatinib are all prescribed as the first-line therapy in NSCLC patients with EGFR sensitizing mutation. Although EGFR mutation-positive patients had favorable treatment response of EGFR TKIs, acquired resistance eventually developed, especially acquired EGFR T790M mutation. The 3rd-generation EGFR TKI, osimertinib, has been approved effectiveness for patients with acquired T790M formation after 1st-and 2nd-generation EGFR TKIs treatment. However, it is unclear whether the incidence of acquired T790M resistance differs as a result of the choice of the first-line EGFR TKI therapy. This study aimed to evaluate the association between the prior EGFR TKI therapy and the incidence of acquired T790M resistance in NSCLC patients who have progressed on EGFR TKI therapy.
Methods
Eligibility included NSCLC patients who had re-biopsy results for testing EGFR T790M mutation from 7 medical centers in Taiwan after June 1, 2013. The primary endpoint is to compare the incidence of acquired T790M mutation in patients who had been treated with different types of EGFR TKIs. Patients harboring tumor with de novo T790M mutations were excluded.
Results
There were 410 patients who received re-biopsy for detection EGFR T790M after treating with 1st- or 2nd- generation EGFR TKIs. The overall acquired T790M mutation rate was 52.9%. Patients treated with gefitinib (59.8%) had higher acquired T790M incidence than those treated with erlotinib (45.5%; p = 0.011), but no difference with those treated with afatinib (53.3%; p = 0.236). Patients who had longer time to treatment discontinuation (TTD) of EGFR TKI for more than 18 months had higher T790M incidence than those with other predefined duration categories (p < 0.001). Multivariate logistic regression analysis revealed common EGFR mutations, gefitinib (compared to erlotinib), and longer TTD of EGFR TKI were associated with higher T790M incidence.
Conclusions
Patients treated with gefitinib had higher acquired T790M incidence than those treated with erlotinib. Longer TTD of EGFR TKI was also associated with the frequency of acquired T790M mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
S-G. Wu: Honoraria (self): Roche; Honoraria (self): AstraZeneca. C-L. Chiang: Honoraria (self): Boehringer Ingelheim; Honoraria (self): Roche. J-Y. Shih: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Novartis; Honoraria (self): Eli Lilly. G-C. Chang: Honoraria (self): F. Hoffmann-La Roche, Ltd; Honoraria (self): AstraZeneca; Honoraria (self): Eli Lilly and Company Oncology; Honoraria (self): Pfizer; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Merck Sharp & Dohme; Honoraria (self): Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract